Keywords: Antineoplastic Agent, Paclitaxel, Radioprotective Agent, Radiosensitizing Agent, Animal, Cell Cycle, Clinical Trial, Dna Damage, Dna Repair, Dose Response, Drug Effect, Drug Resistance, Human, Methodology, Multimodality Cancer Therapy, Neutrophil Chemotaxis, Radiation Exposure, Radiation Response, Review, Leukocyte, Combined Modality Therapy, Dose-Response Relationship, Radiation-Protective Agents, Radiation-Sensitizing Agents,
Affiliations: Radiation Oncology Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, United States
Radiation Biology Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, United States
Radiotherapy Department, Institute of Radiological Sciences, Second University of Naples, Naples, Italy
Thoracic Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States
References: Not available.
Principles of chemoradiation: Theoretical and practical considerations
Chemotherapy agents known to enhance the effects of radiation in preclinical studies have been used concurrently with radiotherapy in numerous clinical trials with the prospect of further enhancing radiation-induced local tumor control. While some success in several tumor histologies has been achieved using this approach, a major concern has been enhancement in normal tissue toxicity. This brief review addresses both theoretical and practical issues with respect to chemoradiation clinical trials. Recommendations for clinical trials are provided that, if implemented, can increase our understanding of basic mechanisms (in patients) and provide a more rational approach for future trials.
Principles of chemoradiation: Theoretical and practical considerations
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(451 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote